CXCR4: C-X-C chemokine receptor type 4
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation.
- Drugs that act on it: 8
- Approved: 2
- In phases 1 to 3: 6
- Sponsors: 7
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CXCR4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Antibody
- Protein or peptide
Approved2
Phase 32
Phase 23
Phase 11
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Ayrmid Pharma113%
- Bristol-Myers Squibb113%
- GPCR Therapeutics, Inc.113%
- Metastatix, Inc.113%
- Polyphor Ltd.113%
- Sanofi113%
- X4 Pharmaceuticals113%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule450%
- Antibody113%
- Protein or peptide338%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 6 of 8 act as: C-X-C chemokine receptor type 4 antagonist; the rest name their own mechanism.| Plerixafor | Approved | Sanofi | Small molecule | Partial agonist | C-X-C chemokine receptor type 4 partial agonist | 29 | — |
| Mavorixafor | Approved | X4 Pharmaceuticals | Small molecule | Antagonist | — | 2 | — |
| Motixafortide | Phase 3 | Ayrmid Pharma | Protein or peptide | Antagonist | — | 6 | — |
| Balixafortide | Phase 3 | Polyphor Ltd. | Protein or peptide | Antagonist | — | 2 | — |
| Burixafor | Phase 2 | GPCR Therapeutics, Inc. | Small molecule | Antagonist | — | 0 | — |
| CTCE-9908 | Phase 2 | — | Protein or peptide | Antagonist | — | 0 | — |
| Ulocuplumab | Phase 2 | Bristol-Myers Squibb | Antibody | Inhibitor | C-X-C chemokine receptor type 4 inhibitor | 0 | — |
| MSX-122 | Phase 1 | Metastatix, Inc. | Small molecule | Antagonist | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- WHIM syndrome
- 0.80
- WHIM syndrome 1
- 0.74
- Plasma cell myeloma
- 0.66
- HIV infectious disease
- 0.58
- Neoplasm
- 0.54
- Lymphoma
- 0.52
- Severe congenital neutropenia
- 0.46
- Skin neoplasm
- 0.40
- B-cell non-Hodgkin lymphoma
- 0.38
- Lymphoid neoplasm
- 0.38
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2107, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P61073, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets